

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



上海復旦張江生物醫藥股份有限公司

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.*

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code:1349)

DETERMINATION OF THE OFFER SIZE AND OFFER PRICE FOR THE ISSUE OF A SHARES AND PROGRESS OF THE PARTICIPATION IN THE STRATEGIC ALLOTMENT UNDER THE ISSUE OF A SHARES BY CONNECTED PERSONS

This announcement is made by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.* (the “**Company**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, of the Laws of Hong Kong).

DETERMINATION OF THE OFFER SIZE AND OFFER PRICE FOR THE ISSUE OF A SHARES

References are made to the announcements of the Company dated 8 March 2019, 12 March 2019, 26 April 2019, 7 May 2019, 13 May 2019, 21 June 2019, 31 July 2019, 29 August 2019, 2 September 2019, 29 September 2019, 10 October 2019, 20 October 2019, 27 October 2019, 31 October 2019, 19 March 2020, 20 March 2020, 25 March 2020, 3 April 2020, 13 April 2020, 14 May 2020, 18 May 2020, 29 May 2020 and 5 June 2020 and the circulars of the Company dated 12 March 2019, 4 April 2019, 6 June 2019 and 4 March 2020 containing, among other things, related matters of the proposed initial public offering of A Shares and listing on the Sci-Tech Innovation Board of the Shanghai Stock Exchange (the “**Shanghai Stock Exchange**”) by the Company (the “**Issue of A Shares**”). Unless

otherwise defined, capitalized terms used in this announcement shall have the meanings as defined in the above announcements and circulars.

The board of directors of the Company (the “**Board**”) is pleased to announce that upon the completion of preliminary price consultation with the price consultation participants on 3 June 2020 and the cumulative tender price consultation with the price consultation participants that provide a valid price quote within the issue price range on 8 June 2020, the Company will issue 120,000,000 shares of A Shares at the offer price of RMB8.95 per A Share. The offer price was negotiated and determined by the Company and the joint lead underwriters based on the result of the price consultation after comprehensively considering the factors such as the fundamentals of the Company, the industry condition, and the price earnings ratio of comparable companies.

For details in relation to the offer price of the Issue of A Shares, please refer to the full text of the “Announcement in Relation to the Offer Price, Subscription of Online Issue and Lot-winning Rate of the Initial Public Offering of Shares and the Listing on the Sci-Tech Innovation Board of the Shanghai Stock Exchange of Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. (《上海復旦張江生物醫藥股份有限公司首次公開發行股票並在科創板上市發行的發行價格、網上發行申購情況及中籤率公告》)” published in Chinese only by the Company on the website of Shanghai Stock Exchange (www.sse.com.cn) on 9 June 2020.

PROGRESS OF THE PARTICIPATION IN THE STRATEGIC ALLOTMENT UNDER THE ISSUE OF A SHARES BY CONNECTED PERSONS

References are made to the announcements of the Company dated 29 April 2019 and 21 June 2019 and the circular of the Company dated 5 June 2019 containing, among other things, the participation in the strategic allotment under the Issue of A Shares by connected persons. As approved by the extraordinary general meeting held by the Company on 21 June 2019, the Company may allot not more than 12,000,000 A Shares to its senior management and core employees under the Issue of A Shares, including not more than 1,000,000 A Shares, 800,000 A Shares, 800,000 A Shares, 600,000 A Shares, 300,000 A Shares and 300,000 A Shares to be allotted to Mr. Wang Hai Bo, Mr. Su Yong, Mr. Zhao Da Jun, Mr. Gan Yi Min, Mr. Wang Luo Chun and Ms. Yu Dai Qing (all being connected persons of the Company), respectively.

The Board is pleased to announce that the Company has determined the final number of shares allotted to senior management and core employees under the Strategic Allotment Plan on 9 June 2020 is 11,934,962 A Shares, and the details of the participation in the strategic allotment under the Issue of A Shares by the connected persons through a special assets management plan (the “**Special Assets Management Plan**”) are as follows:

Name	Position	Amount of Subscription (RMB)	Approximate percentage of the Special Assets Management Plan	Approximate number of shares allotted (0,000 A Shares)
Mr. Wang Hai Bo	Chairman of the Board and general manager of the Company	9,000,000	8.33%	99.42
Mr. Su Yong	Executive Director and deputy general manager of the Company	7,200,000	6.67%	79.61
Mr. Zhao Da Jun	Executive Director and deputy general manager of the Company	7,200,000	6.67%	79.61
Mr. Gan Yi Min	Deputy general manager of the Company and director of Taizhou Fudan-Zhangjiang Pharmaceutical Co. Ltd.* (泰州復旦張江藥業有限公司), a subsidiary of the Company	5,400,000	5.00%	59.67
Mr. Wang Luo Chun	Employee representative Supervisor and director of research and development of the Company	2,160,000	2.00%	23.87
Ms. Yu Dai Qing	Employee representative Supervisor and quality director of the Company	2,700,000	2.50%	29.84

Note: The connected persons do not directly hold the A Shares, but they hold the A Shares through their interests in the Special Assets Management Plan. The above is the calculation of the number of Shares to be allotted to the Special Assets Management Plan and the amount subscribed by each connected person, for illustrative purpose only.

This announcement is for information purposes only and does not constitute an invitation or an offer to acquire, purchase or subscribe for the securities of the Company. The Company will keep the shareholders and potential investors informed of any further development in relation to the Issue of A Shares in accordance with the Listing Rules and applicable laws and regulations.

By order of the Board
Wang Hai Bo
Chairman

As at the date on the publication of this announcement, the Board comprises:

Mr. Wang Hai Bo (Executive Director)
Mr. Su Yong (Executive Director)
Mr. Zhao Da Jun (Executive Director)
Mr. Shen Bo (Non-executive Director)
Ms. Yu Xiao Yang (Non-executive Director)
Mr. Zhou Zhong Hui (Independent Non-executive Director)
Mr. Lam Yiu Kin (Independent Non-executive Director)
Mr. Xu Qing (Independent Non-executive Director)
Mr. Yang Chun Bao (Independent Non-executive Director)

Shanghai, the PRC

9 June 2020

** For identification purpose only*